Anti-CD19 CAR T cells for refractory myasthenia gravis
Authors:
Top Cited Papers
- 15 November 2023
- journal article
- letter
- Published by Elsevier in The Lancet Neurology
- Vol. 22 (12) , 1104-1105
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a studyThe Lancet Neurology, 2023
- CD19-targeted CAR T cells in refractory antisynthetase syndromeThe Lancet, 2023
- CD19-Targeted CAR T Cells in Refractory Systemic Lupus ErythematosusNew England Journal of Medicine, 2021
- Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphomaNature Medicine, 2020
- Immunotherapy in myasthenia gravis in the era of biologicsNature Reviews Neurology, 2018
- Long-Lived Plasma Cells Are Contained within the CD19−CD38hiCD138+ Subset in Human Bone MarrowImmunity, 2015
- Myasthenia gravisNeurology, 2000
- Myasthenia gravisNeurology, 1983